Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Oct 13;128(15):1979-1986.
doi: 10.1182/blood-2016-05-719070. Epub 2016 Aug 22.

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD

Affiliations
Clinical Trial

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD

Raphael Carapito et al. Blood. .

Abstract

Graft-versus-host disease (GVHD) is among the most challenging complications in unrelated donor hematopoietic cell transplantation (HCT). The highly polymorphic MHC class I chain-related gene A, MICA, encodes a stress-induced glycoprotein expressed primarily on epithelia. MICA interacts with the invariant activating receptor NKG2D, expressed by cytotoxic lymphocytes, and is located in the MHC, next to HLA-B Hence, MICA has the requisite attributes of a bona fide transplantation antigen. Using high-resolution sequence-based genotyping of MICA, we retrospectively analyzed the clinical effect of MICA mismatches in a multicenter cohort of 922 unrelated donor HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 10/10 allele-matched HCT pairs. Among the 922 pairs, 113 (12.3%) were mismatched in MICA MICA mismatches were significantly associated with an increased incidence of grade III-IV acute GVHD (hazard ratio [HR], 1.83; 95% confidence interval [CI], 1.50-2.23; P < .001), chronic GVHD (HR, 1.50; 95% CI, 1.45-1.55; P < .001), and nonelapse mortality (HR, 1.35; 95% CI, 1.24-1.46; P < .001). The increased risk for GVHD was mirrored by a lower risk for relapse (HR, 0.50; 95% CI, 0.43-0.59; P < .001), indicating a possible graft-versus-leukemia effect. In conclusion, when possible, selecting a MICA-matched donor significantly influences key clinical outcomes of HCT in which a marked reduction of GVHD is paramount. The tight linkage disequilibrium between MICA and HLA-B renders identifying a MICA-matched donor readily feasible in clinical practice.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of MICA matching on GVHD. The cumulative incidences of grades III-IV acute GVHD (A) and chronic GVHD (B) are shown for mismatched (1) vs matched (2) patients at the MICA locus.
Figure 2
Figure 2
Effect of MICA matching on relapse and NRM. The cumulative incidence of relapse (A) and NRM (B) for mismatched (1) vs matched (2) patients at the MICA locus are shown.
Figure 3
Figure 3
Effect of MICA matching on OS. Kaplan Meier estimates of OS are shown.

References

    1. Forman SJ, Negrin RS, Antin JH, Appelbaum FR. Thomas' Hematopoietic Cell Transplantation. 5th ed. Hoboken, NJ: Wiley-Blackwell; 2016.
    1. Gratwohl A, Pasquini MC, Aljurf M, et al. Worldwide Network for Blood and Marrow Transplantation (WBMT) One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2(3):e91–e100. - PubMed
    1. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443–458. - PMC - PubMed
    1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–1561. - PMC - PubMed
    1. Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124(3):374–384. - PMC - PubMed

Publication types

MeSH terms

Substances